폴햄 남 여 데님 팬츠 6종 택1 16000원대!! 최저가 PHE1DP1033,PHE1DP2029,PHE1DP2024 최고판매가 25,900원
/s/ Joseph B. Armes, /s/ Joseph B. Armes ; Name:, Joseph B. Armes ; Title:, Chairman of the Board,
폴햄 남 여 데님 팬츠 6종 택1 16000원대!! 최저가 PHE1DP1033,PHE1DP2029,PHE1DP2024 최고판매가 25,900원
모델번호 : MJL025 15AUF0031, 상품코드 : uM7339047023, 배송정보 : 해외배송 (택배), 배송비 : 무료배송 예상기간 : 영업일 기준 평군 14일, 상품상태 : 새상품, 원산지(제조국) : ITALY (적출국)
Item 2.02. Results of Operations and Financial Condition. The registrant’s press release dated April 16, 2019, regarding its financial results for the periods ended March 31, 2019, including consolidated financial statements for the periods ended March 31, 2019, is Exhibit 99.1 of this Form 8-K. In an effort to provide investors with additional information regarding the company’s results as determined by generally accepted accounting principles (GAAP), the company has disclosed in the attach...
폴햄 데님 팬츠 6종 택1 PHE1DP1033,PHE1DP2029,PHE1DP2024,PHE1DP2026,PHE1DP1039,PHE1DP106615%22,015원
Item 7.01 Regulation FD Disclosure. On January 3, 2019, BioXcel Therapeutics, Inc. (the “Company”) held an investor conference call and discussed the results of the study described in Item 8.01 below and the Company’s BXCL501 program. In connection with the investor call, the Company prepared presentation materials (“the Presentation Materials”), a copy of which are furnished as Exhibit 99.1 to this current report on Form 8-K. The call will be available via a live, listen-only webcast ...
Item 7.01 (Regulation FD Disclosure) ; Attachment I contains presentation materials for IBM’s Investor Briefing on February 26, 2015. Attachment II (Non-GAAP Supplementary Materials) contains supplementary materials about non-GAAP financial measures in certain presentation materials for this event. As part of the Investor Briefing, IBM’s senior executives are prepared to provide the following information, which is hereby filed: The company continues to expect to deliver $15.75 to $16.50 of o...
Item 7.01 (Regulation FD Disclosure) ; Exhibit 99.1 contains IBM’s presentation materials for IBM’s Investor Briefing on March 8, 2018. The information in this Item 7.01, including the corresponding Exhibit 99.1, is being furnished with the Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”). In an effort to provide investors with additional information regarding the company’s results as determined by gen...
Item 7.01 (Regulation FD Disclosure) ; Attachment I contains presentation materials for IBM’s Investor Briefing on March 8, 2011. Attachment II (Non-GAAP Supplementary Materials) contains supplementary materials about non-GAAP financial measures in certain presentation materials for this event. IBM’s web site (www.ibm.com) contains a significant amount of information about IBM, including financial and other information for investors (www.ibm.com/investor/). IBM encourages investors to visit ...